$JANX
Janux Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000095017022004171 Filed on March 18, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $1.616M $3.637M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.937M $10.33M $670.0K
YoY Change 487.61% 473.2%
% of Gross Profit
Research & Development $11.17M $26.24M $990.0K
YoY Change 1028.18% 762.78%
% of Gross Profit
Depreciation & Amortization $64.00K $113.0K $9.000K
YoY Change 611.11% 769.23%
% of Gross Profit
Operating Expenses $15.11M $26.24M $1.655M
YoY Change 812.75% 762.78%
Operating Profit -$32.93M
YoY Change 579.93%
Interest Expense $74.00K $257.0K $0.00
YoY Change -113.24%
% of Operating Profit
Other Income/Expense, Net $257.0K
YoY Change -113.24%
Pretax Income -$13.42M -$32.67M -$1.655M
YoY Change 710.63% 381.6%
Income Tax
% Of Pretax Income
Net Earnings -$13.42M -$32.67M -$1.655M
YoY Change 710.63% 381.6%
Net Earnings / Revenue -830.2% -898.32%
Basic Earnings Per Share -$1.39
Diluted Earnings Per Share -$324.0K -$1.389M -$41.48K
COMMON SHARES
Basic Shares Outstanding 41.61M 445.3K
Diluted Shares Outstanding 23.53M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $375.0M $375.0M
YoY Change 4699.24%
Cash & Equivalents $35.58M $35.58M $7.813M
Short-Term Investments $339.4M $339.4M
Other Short-Term Assets $2.054M $2.054M
YoY Change 724.9%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $8.000M
Other Receivables $0.00 $0.00
Total Short-Term Assets $377.0M $377.0M $16.06M
YoY Change 2247.27% 2247.27%
LONG-TERM ASSETS
Property, Plant & Equipment $1.412M $1.597M $155.0K
YoY Change 810.97% 930.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $392.0K $1.208M $0.00
YoY Change
Total Long-Term Assets $2.805M $2.805M $155.0K
YoY Change 1709.68% 1709.68%
TOTAL ASSETS
Total Short-Term Assets $377.0M $377.0M $16.06M
Total Long-Term Assets $2.805M $2.805M $155.0K
Total Assets $379.8M $379.8M $16.22M
YoY Change 2242.13% 2242.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.458M $2.458M $428.0K
YoY Change 474.3% 474.3%
Accrued Expenses $3.779M $3.973M $751.0K
YoY Change 403.2% 429.03%
Deferred Revenue $5.163M $1.950M
YoY Change 164.77%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.80M $12.80M $3.181M
YoY Change 302.29% 302.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $700.0K $700.0K
YoY Change -88.43%
Total Long-Term Liabilities $700.0K $700.0K
YoY Change -88.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.80M $12.80M $3.181M
Total Long-Term Liabilities $700.0K $700.0K
Total Liabilities $13.50M $13.50M $9.231M
YoY Change 46.21% 46.21%
SHAREHOLDERS EQUITY
Retained Earnings -$47.41M -$14.74M
YoY Change 221.67%
Common Stock $414.0M $101.0K
YoY Change 409808.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $366.3M $366.3M -$14.64M
YoY Change
Total Liabilities & Shareholders Equity $379.8M $379.8M $16.22M
YoY Change 2242.13% 2242.13%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$13.42M -$32.67M -$1.655M
YoY Change 710.63% 381.6%
Depreciation, Depletion And Amortization $64.00K $113.0K $9.000K
YoY Change 611.11% 769.23%
Cash From Operating Activities -$10.48M -$16.98M -$1.629M
YoY Change 543.4% 288.56%
INVESTING ACTIVITIES
Capital Expenditures -$1.173M $1.482M $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.499M -$339.5M
YoY Change
Cash From Investing Activities $7.326M -$341.0M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 164.0K 386.5M 4.553M
YoY Change -96.4% 3254.08%
NET CHANGE
Cash From Operating Activities -10.48M -16.98M -1.629M
Cash From Investing Activities 7.326M -341.0M 0.000
Cash From Financing Activities 164.0K 386.5M 4.553M
Net Change In Cash -2.991M 28.59M 2.924M
YoY Change -202.29% 299.51%
FREE CASH FLOW
Cash From Operating Activities -$10.48M -$16.98M -$1.629M
Capital Expenditures -$1.173M $1.482M $0.00
Free Cash Flow -$9.308M -$18.46M -$1.629M
YoY Change 471.39% 322.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Registrant Name
EntityRegistrantName
Janux Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2289112
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
11099 N. Torrey Pines Road, Suite 290
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001817713
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40475
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Local Phone Number
LocalPhoneNumber
750-4700
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
JANX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
525700000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41622962
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35582000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7813000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
339383000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2054000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
249000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
377019000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
16062000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
816000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1412000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
185000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
392000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2021Q4 us-gaap Assets
Assets
379824000
CY2020Q4 us-gaap Assets
Assets
16217000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2458000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
428000
CY2021Q4 janx Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
32000
CY2020Q4 janx Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
544000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3779000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
751000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5163000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1950000
CY2021Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
1203000
CY2020Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
52000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
194000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12797000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3181000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
700000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6050000
CY2021Q4 us-gaap Liabilities
Liabilities
13497000
CY2020Q4 us-gaap Liabilities
Liabilities
9231000
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
6838829
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6838829
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6838829
CY2021Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
21709000
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
21624000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
9000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41622962
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257736
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41243137
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1046599
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
413967000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
100000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47411000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14739000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
366327000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-14638000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
379824000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16217000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3637000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26237000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3041000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10329000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1802000
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
36566000
CY2020 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
4843000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-32929000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-4843000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
257000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
0
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2020 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
206000
CY2021 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
0
CY2020 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
-1735000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
257000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1941000
CY2021 us-gaap Profit Loss
ProfitLoss
-32672000
CY2020 us-gaap Profit Loss
ProfitLoss
-6784000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-270000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-32942000
CY2020 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6784000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.41
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23530252
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
915146
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-7944000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
72000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6784000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-14638000
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
202171000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
204167000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
164000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
475000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6910000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-270000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-32672000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
366327000
CY2021 us-gaap Profit Loss
ProfitLoss
-32672000
CY2020 us-gaap Profit Loss
ProfitLoss
-6784000
CY2021 us-gaap Depreciation
Depreciation
113000
CY2020 us-gaap Depreciation
Depreciation
13000
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6910000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
72000
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2020 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
206000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
172000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2021 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
0
CY2020 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
-1735000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8000000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1805000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
249000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
392000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2139000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14000
CY2021 janx Accrued Expenses Includes Related Party Amounts
AccruedExpensesIncludesRelatedPartyAmounts
-512000
CY2020 janx Accrued Expenses Includes Related Party Amounts
AccruedExpensesIncludesRelatedPartyAmounts
442000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3028000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
624000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2137000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
8000000
CY2021 janx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-9000
CY2020 janx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16976000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4369000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1482000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
473626000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
134145000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-340963000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2021 janx Proceeds From Issuance Of Convertible Promissory Notes
ProceedsFromIssuanceOfConvertiblePromissoryNotes
0
CY2020 janx Proceeds From Issuance Of Convertible Promissory Notes
ProceedsFromIssuanceOfConvertiblePromissoryNotes
2500000
CY2021 janx Proceeds From Exercise Of Vested And Unvested Common Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfVestedAndUnvestedCommonStockOptionsAndEmployeeStockPurchasePlan
1810000
CY2020 janx Proceeds From Exercise Of Vested And Unvested Common Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfVestedAndUnvestedCommonStockOptionsAndEmployeeStockPurchasePlan
70000
CY2020 janx Conversion Of Convertible Promissory Notes And Accrued Interest Into Shares Of Convertible Preferred Stock
ConversionOfConvertiblePromissoryNotesAndAccruedInterestIntoSharesOfConvertiblePreferredStock
8674000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
38000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
147000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
204167000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
386524000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2021 janx Conversion Of Convertible Promissory Notes And Accrued Interest Into Shares Of Convertible Preferred Stock
ConversionOfConvertiblePromissoryNotesAndAccruedInterestIntoSharesOfConvertiblePreferredStock
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11524000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
28585000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7155000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7813000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
658000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36398000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7813000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
202171000
CY2021 janx Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
475000
CY2020 janx Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
2000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-270000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2021 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
256000
CY2020 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
CY2021 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
Company’s certificate of incorporation to effect a forward split of shares of the Company’s common stock on a one-for-1.281 basis, which was effected on June 4, 2021 (the “Forward Stock Split”). The number of authorized shares and the par values of the common stock and convertible preferred stock were not adjusted as a result of the Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the Forward Stock Split for all periods presented.
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.281
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47400000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
816000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to estimates to complete the performance obligations and the estimated transaction price for collaboration revenue, accruals for research and development expenses, stock-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">readily </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">apparent from other sources. Although the impact of the COVID-19 pandemic to the Company’s business and operating results presents additional uncertainty, the Company continues to use the best information available to update its accounting estimates. Actual results may differ materially and adversely from these estimates.</span></p>
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25018000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
339383000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
816000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
365217000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35582000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7813000
CY2021 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36398000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7813000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
339653000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
277000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
339383000
CY2021Q4 us-gaap Financing Receivable Accrued Interest Before Allowance For Credit Loss
FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss
200000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
445326
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
291267000
CY2021Q4 janx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
48116000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
29
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
248800000
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
300000
CY2021Q4 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
233726
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentrations of Credit Risk</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has not experienced any losses in such account and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is also subject to credit risk from its accounts receivable. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. As of December 31, 2021 and December 31, 2020, all of the Company’s accounts receivable, if any, relate to a single customer. For the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, all of the Company’s revenue related to a single customer.</span>
CY2021 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6039717
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10068205
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1543000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
176000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
131000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1412000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
286000
CY2021Q4 janx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2130000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.16
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1171000
CY2020Q4 janx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
66000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
478000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
399000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3779000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
751000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
198000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
198000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
194000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
194000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2021Q4 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextTwelveMonths
0
CY2021Q4 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Two Years
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextTwoYears
3040000
CY2021Q4 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Three Years
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextThreeYears
3412000
CY2021Q4 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Four Years
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextFourYears
3514000
CY2021Q4 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Five Years
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextFiveYears
3620000
CY2021Q4 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueThereafter
24115000
CY2021Q4 janx Lessee Operating Lease Liability Payments Not Yet Commenced
LesseeOperatingLeaseLiabilityPaymentsNotYetCommenced
37701000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
6838829
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6838829
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6838829
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
21709000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
21624000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1096533
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.47
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M21D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3214000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5230595
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.69
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
635316
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.59
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37149
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.65
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5066553
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.37
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5654663
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
62954000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5654663
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.65
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y2M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
62954000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
62645000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.01
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.44
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000.0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
35400000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 janx Percentage Of Number Of Common Stock Shares
PercentageOfNumberOfCommonStockShares
0.01
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6910000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
72000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
211137
CY2020Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
52000
CY2021 janx Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedShares
521896
CY2021 janx Unvested Stock Liabilities Early Exercised Shares
UnvestedStockLiabilitiesEarlyExercisedShares
1626000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
353208
CY2021 janx Unvested Stock Liabilities Vested Shares
UnvestedStockLiabilitiesVestedShares
475000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
379825
CY2021Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
1203000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9738250
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10077215
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8000000.0
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y3M18D
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000000.0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6861000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1425000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2169000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-426000
CY2021 janx Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
324000
CY2020 janx Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
410000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-745000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-338000
CY2021 janx Income Tax Reconciliation Reserves For Uncertain Tax Positions
IncomeTaxReconciliationReservesForUncertainTaxPositions
253000
CY2020 janx Income Tax Reconciliation Reserves For Uncertain Tax Positions
IncomeTaxReconciliationReservesForUncertainTaxPositions
85000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
328000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8870000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1694000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3731000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11134000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1179000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
703000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1273000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
21000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
131000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13717000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4456000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13390000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4444000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
327000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
106000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
9000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
221000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
3000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
327000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
12000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
234000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
149000
CY2021 janx Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-50000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
326000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
85000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
510000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
234000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
500000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
200000
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.03

Files In Submission

Name View Source Status
0000950170-22-004171-index-headers.html Edgar Link pending
0000950170-22-004171-index.html Edgar Link pending
0000950170-22-004171.txt Edgar Link pending
0000950170-22-004171-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img109799880_0.jpg Edgar Link pending
img109799880_1.jpg Edgar Link pending
img109799880_10.jpg Edgar Link pending
img109799880_11.jpg Edgar Link pending
img109799880_12.jpg Edgar Link pending
img109799880_13.jpg Edgar Link pending
img109799880_14.jpg Edgar Link pending
img109799880_15.jpg Edgar Link pending
img109799880_16.jpg Edgar Link pending
img109799880_17.jpg Edgar Link pending
img109799880_18.jpg Edgar Link pending
img109799880_19.jpg Edgar Link pending
img109799880_2.jpg Edgar Link pending
img109799880_20.jpg Edgar Link pending
img109799880_21.jpg Edgar Link pending
img109799880_22.jpg Edgar Link pending
img109799880_23.jpg Edgar Link pending
img109799880_24.jpg Edgar Link pending
img109799880_25.jpg Edgar Link pending
img109799880_26.jpg Edgar Link pending
img109799880_27.jpg Edgar Link pending
img109799880_28.jpg Edgar Link pending
img109799880_29.jpg Edgar Link pending
img109799880_3.jpg Edgar Link pending
img109799880_30.jpg Edgar Link pending
img109799880_31.jpg Edgar Link pending
img109799880_32.jpg Edgar Link pending
img109799880_4.jpg Edgar Link pending
img109799880_5.jpg Edgar Link pending
img109799880_6.jpg Edgar Link pending
img109799880_7.jpg Edgar Link pending
img109799880_8.jpg Edgar Link pending
img109799880_9.jpg Edgar Link pending
img192204503_0.jpg Edgar Link pending
img193128024_0.jpg Edgar Link pending
img194975066_0.jpg Edgar Link pending
img194975066_1.jpg Edgar Link pending
img194975066_2.jpg Edgar Link pending
img194975066_3.jpg Edgar Link pending
img194975066_4.jpg Edgar Link pending
img194975066_5.jpg Edgar Link pending
img194975066_6.jpg Edgar Link pending
janx-20211231.htm Edgar Link pending
janx-20211231.xsd Edgar Link pending
janx-20211231_cal.xml Edgar Link unprocessable
janx-20211231_def.xml Edgar Link unprocessable
janx-20211231_htm.xml Edgar Link completed
janx-20211231_lab.xml Edgar Link unprocessable
janx-20211231_pre.xml Edgar Link unprocessable
janx-ex10_14.htm Edgar Link pending
janx-ex10_15.htm Edgar Link pending
janx-ex10_17.htm Edgar Link pending
janx-ex23_1.htm Edgar Link pending
janx-ex31_1.htm Edgar Link pending
janx-ex31_2.htm Edgar Link pending
janx-ex32_1.htm Edgar Link pending
janx-ex4_4.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending